Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: MIRM

Mirum Pharmaceuticals, Inc.

Healthcare | Biotechnology

Market prices for MIRM are shown to signed-in users (sign in). This public page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-14.54

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 20:48 UTC.

What Mirum Pharmaceuticals, Inc. does

Mirum Pharmaceuticals is a biopharmaceutical company focused on rare diseases with three approved medicines: Livmarli for cholestatic pruritus and progressive familial intrahepatic cholestasis, Cholbam for bile acid synthesis disorders and peroxisomal disorders, and Ctexli for cerebrotendinous xanthomatosis. The company markets these medicines in the United States, Canada, and select European countries through its own commercial team, and has entered into license and distribution agreements for additional territories.

Summarized from Mirum Pharmaceuticals, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-14.54

Revenue, margins & earnings

FY2021: net loss $84M on revenue $19M$19MFY2021FY2022: net loss $136M on revenue $77M$77MFY2022FY2023: net loss $163M on revenue $186M$186MFY2023FY2024: net loss $88M on revenue $337M$337MFY2024FY2025: net loss $23M on revenue $521M$521MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-19
  • 2026-10-19SVP, GLOBAL CONTROLLEROption exercise16,112$310.0K
  • 2026-10-19SVP, GLOBAL CONTROLLEREmployee Stock Option (right to buy)Option exercise-16,112—
  • 2026-10-14Chief Medical OfficerRestricted Stock UnitsAward25,000—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Mirum Pharmaceuticals, Inc. do?

Mirum Pharmaceuticals, Inc. is a biotechnology company, listed on NASDAQ as MIRM.

When did MIRM last file with the SEC?

Mirum Pharmaceuticals, Inc.'s most recent SEC filing on record is a 8-K filed 2026-10-13. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 20:48 UTC. This page is also available as JSON at /api/data?ticker=MIRM and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for MIRM and 5,000+ tickers.

Create a free account — keep MIRM
For your agent
GET /api/data?ticker=MIRM

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt